Lifeward Ltd. current report, 15 May 2018

Business Context and Reporting Period

This Form 8-K is filed by ReWalk Robotics Ltd. (not Lifeward Ltd.) for the reporting period of May 15, 2018. The filing reports the completion of the first tranche of a strategic investment agreement with Timwell Corporation Limited and the appointment of a new director to the Board.

Key Financial Metrics

  • Cash Proceeds: The Company received $5.0 million from the Investor upon the First Tranche Closing.
  • Share Issuance: 4,000,000 ordinary shares were issued at a price of $1.25 per share.
  • Ownership Stake: Post-transaction, the Investor beneficially owns approximately 11.6% of the Company's ordinary shares.
  • Outstanding Shares: 30,633,885 ordinary shares outstanding as of May 15, 2018 (excluding shares issuable upon conversion or exercise of derivative securities).
  • Director Compensation: The new director will receive Restricted Stock Units (RSUs) valued at $30,000 on the grant date, with annual grants of $25,000 thereafter.

Note: The filing does not provide data on revenue, profit, operating margins, total debt, or liquidity positions beyond the specific transaction proceeds.

Material Changes

  • Capital Structure: The Company completed the First Tranche Closing of a $20.0 million total investment agreement, receiving the initial $5.0 million tranche.
  • Board Composition: Ms. Ning Cong was appointed to the Board of Directors as a Class II director, effective immediately, representing the Investor.
  • Regulatory Status: The share issuance was conducted as an unregistered sale of equity securities, exempt under Regulation S and Section 4(a)(2) of the Securities Act.

Outlook, Risks, and Management Commentary

  • Future Tranches: The Investment Agreement provides for two additional tranches: $10.0 million for 8,000,000 shares (Second Tranche) and $5.0 million for 4,000,000 shares (Third Tranche).
  • Investor Background: The Investor, Timwell Corporation Limited, is a Hong Kong corporation. The new director, Ms. Cong, brings experience in healthcare private equity and strategic partnerships in China.
  • Compensation Terms: Director RSUs vest quarterly over one year, with acceleration upon certain change of control events.
  • Risks: The filing notes that the press release furnished with the report is not deemed "filed" for purposes of Section 18 of the Exchange Act.

Key Facts for Investor Verification

  • Verify the conditions precedent for the Second and Third tranches of the $20.0 million investment.
  • Confirm the total number of shares outstanding including any convertible securities or options not included in the 30,633,885 figure cited.
  • Review the full text of the Investment Agreement for covenants or restrictions associated with the Timwell Corporation Limited investment.
  • Assess the impact of the 11.6% ownership stake held by the Investor on future corporate governance and strategic direction.